Aditxt, Inc., a biotech company specializing in immune modulation technology, has announced the offering of 677,208 shares of common stock and pre-funded warrants to purchase an additional 3,366,297 shares. The offering is part of the company's efforts to raise capital for research and development, as well as for general corporate purposes. The pre-funded warrants provide investors with the option to purchase shares of Aditxt's common stock at a predetermined price. The announcement did not specify the pricing or timing of the offering, nor did it detail the use of proceeds beyond general statements. This move is aimed at providing the company with necessary funds to advance its product pipeline and support its growth strategy.

Aditxt, Inc., a biotech company specializing in immune modulation technology, has announced the offering of 677,208 shares of common stock and pre-funded warrants to purchase an additional 3,366,297 shares. The offering is part of the company's efforts to raise capital for research and development, as well as for general corporate purposes. The pre-funded warrants provide investors with the option to purchase shares of Aditxt's common stock at a predetermined price. The announcement did not specify the pricing or timing of the offering, nor did it detail the use of proceeds beyond general statements. This move is aimed at providing the company with necessary funds to advance its product pipeline and support its growth strategy.